TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31888575
Drug: Mexican Guideline
Normalized name: Mexican tea pollen extract
DrugBank: Chenopodium ambrosioides pollen (DB10479)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexican Guideline Daily Allowances (GDA)
Study: 27213837
Drug: Antiresorptive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiresorptive therapy (AT)
Study: 22956219
Drug: Lacteol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacteol (2 capsules/day) for 4 weeks
Study: 16080280
Drug: 180 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mg diclofenac epolamine plaster (reference preparation)
Study: 12695914
Drug: Glycerol hyperhydration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerol hyperhydration (1.2 g kg(‐1) body mass glycerol mixed with 21 ml kg(‐1) body mass flavoured water)
Study: 15673385
Drug: No antiarrhythmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiarrhythmic drug therapy
Study: 8987192
Drug: HbOC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HbOC vaccine immunization scheme and a booster dose at 15 months of age
Study: 3881710
Drug: Triple-dose cefotaxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-dose cefotaxime
Study: 30321667
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (initial bolus dose of 2500 μg cholecalciferol followed by 100 μg cholecalciferol/d)
Study: 22305377
Drug: 450 mg
Normalized name: aspirin 450 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg valganciclovir
Study: 22305377
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg valganciclovir
Study: 11392580
Drug: omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole 40 mg once a day for 8 weeks
Study: 8064597
Drug: Piroxicam (Feldene,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam (Feldene, 20 mg daily)
Study: 24923656
Drug: 1-g mesalazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-g mesalazine suppository
Study: 9059138
Drug: Sulphasalazine 2-3
Normalized name: sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulphasalazine 2-3 g per day (n = 37)
Study: 8448068
Drug: Isradipine sustained
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine sustained release (I-SRO) 5 mg PM
Study: 17110413
Drug: Vitamins C
Normalized name: MULTIVITAMINS CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamins C (2 g) and E (400 IU) given 2 h before a second dive
Study: 15288288
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose (12 Gy) brachytherapy
Study: 15785149
Drug: Adjusted-dose warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted-dose warfarin (INR 2.0-3.0)
Study: 18372254
Drug: FSH-only preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSH-only preparations following a low-dose step-up protocol
Study: 12850192
Drug: p53 gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: p53 gene therapy in combination with standard chemotherapy
Study: 8990505
Drug: Topical R-85355
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical R-85355
Study: 1473919
Drug: Ioxaglate administered
Normalized name: ioxaglate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ioxaglate administered intravenously
Study: 24477835
Drug: BCAA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA supplementation (5 g day(‐1) of powdered 1:0.5:0.5 leucine:isoleucine:valine)
Study: 11468025
Drug: Calculated dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calculated dose (CD) using Bayesian methodology
Study: 11468025
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose (LD) of 25 mg/kg body weight
Study: 11468025
Drug: Calculated dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calculated dose (CD)
Study: 11468025
Drug: Calculated dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calculated dose (CD) in ventilated patients
Study: 9706734
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) adjunctive therapy
Study: 8156738
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic factor (10 ng min‐1 100 ml‐1 forearm volume)
Study: 8156738
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside (equipotent vasodilator dose)
Study: 3279775
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg per day of ketoconazole
Study: 3279775
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg per day of ketoconazole
Study: 28640136
Drug: Prescription of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription of physical activity (PPA)
Study: 18342223
Drug: Clopidogrel 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 600 mg the day before (>or=15 h) and 600 mg the morning of the procedure (>or=2 h) (Group C)
Study: 18342223
Drug: Clopidogrel 300
Normalized name: clopidogrel 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 300 mg the day before (>or=15 h) + 75 mg the morning of the procedure (Group A)
Study: 9255192
Drug: Crossover treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover treatment with iNO after HFOV failure
Study: 9255192
Drug: Crossover treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover treatment with HFOV after iNO failure
Study: 3625231
Drug: Single 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 2 h infusion of 500 mg of 9.2.27
Study: 3625231
Drug: Five daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five daily 2 h infusions of 100 mg of 9.2.27
Study: 3625231
Drug: Interruption in
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interruption in therapy for 4 weeks
Study: 3625231
Drug: Initial infusions
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial infusions of 500 mg of 9.2.27
Study: 3625231
Drug: Monitoring antiglobulin
Normalized name: immunoglobulin G, human Injectable Solution [Kabiglobulin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monitoring antiglobulin levels during therapy
Study: 31547827
Drug: Primaquine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine (0.5 mg/kg/day for 7-9 days)
Study: 28962948
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy (CCRT) with thoracic radiotherapy (50 Gy in 25 fractions) and five cycles of weekly paclitaxel (50 mg/m2) and cisplatin (25 mg/m2), followed by two additional cycles of paclitaxel (175 mg/m2) plus cisplatin (80 mg/m2) at 3-week intervals.
Study: 28962948
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with four cycles of adjuvant paclitaxel (175 mg/m2) and carboplatin (AUC = 5.5) every 3 weeks.
Study: 21390165
Drug: Fentanyl 20
Normalized name: fentaNYL 200 mcg buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 20 µg
Study: 21390165
Drug: Sufentanil 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 2.5 µg
Study: 20032609
Drug: Bethanechol administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bethanechol administration during radiotherapy
Study: 18693589
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (MMC‐40) 40 mg instilled within 30 minutes of TUR
Study: 310412
Drug: Gastrozepin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrozepin therapy
Study: 19336728
Drug: Bicalutamide 50
Normalized name: bicalutamide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide 50 mg/wk
Study: 19336728
Drug: Bicalutamide 100
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bicalutamide 100 mg/wk
Study: 17899572
Drug: Progesterone vaginal
Normalized name: progesterone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone vaginal gel
Study: 11916619
Drug: Antibiotic-soak group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic-soak group (gentamicin solution for approximately 2 min)
Study: 9785777
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia (TIVA) with propofol and fentanyl (group P, n = 107)
Study: 9785777
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia (TIVA) with propofol and fentanyl (group P)
Study: 2715803
Drug: MOPP chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOPP chemotherapy (CT) - six courses
Study: 1052105
Drug: Tinidazole (Fasigyn-Pfizer)
Normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tinidazole (Fasigyn-Pfizer) - 2 grammes as a single oral dose
Study: 31524770
Drug: Branched-chain amino
Normalized name: Branched-chain amino acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branched-chain amino acid granules (12 g of branched-chain amino acid)
Study: 11355560
Drug: Albendazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (400 mg single dose)
Study: 7803947
Drug: Monoamine oxidase
Normalized name: Monoamine oxidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoamine oxidase inhibitors
Study: 8476408
Drug: Behaviour therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behaviour therapy
Study: 8078530
Drug: Budesonide (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (9 mg per day for 8 weeks, then 6 mg per day for 2 weeks)
Study: 8078530
Drug: Prednisolone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (40 mg per day for 2 weeks, then gradually reduced to 5 mg per day)
Study: 829223
Drug: Local VM
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local VM 26 chemotherapy after TUR
Study: 17393216
Drug: 4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/day DHA-rich fish oil
Study: 8534465
Drug: Dezocine 6
Normalized name: DEZOCINE
DrugBank: Dezocine (DB01209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dezocine 6 mg IV
Study: 8534465
Drug: Ketorolac 60
Normalized name: ketorolac 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 60 mg IV
Study: 7003457
Drug: Levamisole (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (50 mg t.i.d. for 3 consecutive days every 2 weeks)
Study: 31270173
Drug: MenB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenB vaccine (Bexsero)
Study: 31270173
Drug: Other meningococcal
Normalized name: other meningococcal monovalent purified polysaccharides antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other meningococcal vaccines (57 adults)
Study: 28027445
Drug: Osteopathic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic treatment coupled with usual lactation consultations
Study: 26391602
Drug: 2.4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 g/day oral mesalazine
Study: 26391602
Drug: 4.8 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.8 g/day oral mesalazine
Study: 23206372
Drug: Two-phase treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-phase treatment starting in mixed dentition
Study: 19237900
Drug: NIV with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIV with low internal volume mask (163 mL)
Study: 30391169
Drug: Rupatadine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rupatadine 20 mg
Study: 17478385
Drug: Rupatadine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rupatadine 10 mg and 20 mg
Study: 17478385
Drug: Rupatadine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rupatadine 5 mg
Study: 27492833
Drug: Aclidinium/formoterol 400/12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aclidinium/formoterol 400/12 µg twice-daily
Study: 27492833
Drug: Salmeterol/fluticasone 50/500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone 50/500 µg twice-daily
Study: 15462115
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (symptomatic treatment)
Study: 16638030
Drug: Subcutaneous sterile
Normalized name: Steril-Eyes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous sterile water injection (0.5 mL)
Study: 12785471
Drug: CBASP (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBASP (both alone and with medication)
Study: 9008516
Drug: High plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: High plasma valproate group (80 to 150 micrograms/mL)
Study: 9008516
Drug: Low plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low plasma valproate group (25 to 50 micrograms/mL)
Study: 8474315
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) 24 IU
Study: 25038306
Drug: Intensive intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive intervention (LDL-C target <100 mg/dL, switching ART if needed, low-dose aspirin)
Study: 25038306
Drug: Standard intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intervention (LDL-C target <130 mg/dL)
Study: 23226979
Drug: Oral hyaluronic
Normalized name: hyaluronate Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hyaluronic acid (HA) 200 mg once a day for 12 months
Study: 10189602
Drug: Sertraline (50-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50-150 mg)
Study: 28935140
Drug: d-Allulose (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-Allulose (5 g)
Study: 28935140
Drug: Aspartame (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame (10 mg)
Study: 11736893
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro cytotoxicity model using HaCaT cells with various irritants (100 µL of 20 mmol L(‐1) aqueous solution)
Study: 11736893
Drug: In vivo
Normalized name: IMAGING AGENTS (IN VIVO) RADIOPHARMACEUTICALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vivo irritation potential in humans after 24-hour application of the same compounds
Study: 3147905
Drug: Cholestyramine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine (3 x 12 g daily for 4 weeks)
Study: 3147905
Drug: Cholestyramine (acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine (acute and chronic administration)
Study: 28425029
Drug: AAFP 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAFP 125 mg, 500 mg, 625 mg
Study: 30340765
Drug: Rivaroxaban 2.5
Normalized name: rivaroxaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 2.5 mg BID
Study: 30340765
Drug: Rivaroxaban 5
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban 5 mg BID
Study: 25318481
Drug: Rivaroxaban (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (both doses combined)
Study: 18926940
Drug: Alkaline mineral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkaline mineral water (water B) rich in bicarbonate (per litre: 547 mg Ca, 2172 mg HCO(3)(‐), 9 mg SO(4)(‐), PRAL ‐11.2 mEq)
Study: 18926940
Drug: Acid calcium-rich
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acid calcium-rich water (water A) (per litre: 520 mg Ca, 291 mg HCO(3)(‐), 1160 mg SO(4)(‐), PRAL +9.2 mEq)
Study: 28837210
Drug: Extended anticoagulation
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended anticoagulation with vitamin K antagonists
Study: 23708468
Drug: Standard psychosocial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard psychosocial treatment
Study: 21592879
Drug: Amlodipine/valsartan 10/320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/valsartan 10/320 mg
Study: 12745039
Drug: Acetaminophen (ACET)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (ACET) 1000 mg
Study: 8623187
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) - enoxaparin 40 mg/day
Study: 3006619
Drug: Enalapril (EN)
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril (EN) 20 mg once-a-day
Study: 29757924
Drug: Ketamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusion (40 μg kg min over 5 min followed by 2.5 μg kg min)
Study: 29757924
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline infusion (control group)
Study: 24287940
Drug: DEP 75
Normalized name: Endep 75 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEP 75 mg
Study: 24287940
Drug: MZD 2
Normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MZD 2 mg
Study: 24287940
Drug: SIB 15
Normalized name: duvelisib 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIB 15 mg
Study: 22408266
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of antidepressant treatment (68 patients)
Study: 17728419
Drug: Adjunctive antidepressant
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive antidepressant use
Study: 12453326
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) 425 mg/m2 with low-dose folinic acid (FA) 20 mg/m2, administered as a rapid bolus intravenous injection for 5 days every 4-5 weeks
Study: 12453326
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) with low-dose folinic acid (FA)
Study: 10445530
Drug: Erythromycin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (3 mg/kg) administered intravenously over 15 min before consumption of 300 g minced beef and 150 ml water.
Study: 7556858
Drug: Slow injection
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow injection of local anesthetic into one side of the cervix
Study: 9673264
Drug: Acellular vaccine
Normalized name: PERTUSSIS VACCINE,ACELLULAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular vaccine
Study: 7677415
Drug: Whole cell
Normalized name: pertussis, whole cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole cell vaccine
Study: 2300411
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of acellular vaccine
Study: 30465917
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate supplementation (1500 mg Ca/d)
Study: 23498899
Drug: Instant coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instant coffee containing 3 mg of caffeine/kg body weight
Study: 23498899
Drug: Instant coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instant coffee containing 6 mg of caffeine/kg body weight
Study: 19124484
Drug: Coexpression of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coexpression of alpha6beta4 integrin and Net1 in hormone receptor-positive tumors
Study: 17475318
Drug: Other sources
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other sources (e.g., word of mouth)
Study: 15127079
Drug: Mifepristone (RU-486)
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mifepristone (RU-486) 600 mg/day
Study: 28388932
Drug: Sodium benzoate
Normalized name: Sodium Benzoate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium benzoate (1000 mg, 500 mg twice daily for 12 weeks)
Study: 24282343
Drug: Bridging treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bridging treatments (transarterial chemoembolization, radiofrequency ablation, surgical resection)
Study: 24282343
Drug: Bridging treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bridging treatments
Study: 24282343
Drug: Downstaging treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Downstaging treatments
Study: 20883846
Drug: Warm Water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm Water Infusion (WWI)
Study: 18413618
Drug: 90-microL testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 90-microL testosterone metered-dose transdermal spray
Study: 15899748
Drug: 20-minute self-administered
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-minute self-administered intervention with normative feedback and goal setting
Study: 10343191
Drug: Oral medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral medroxyprogesterone acetate 1,200 mg (arm I)
Study: 10343191
Drug: Oral medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral medroxyprogesterone acetate 600 mg (arm II)
Study: 10343191
Drug: Oral medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral medroxyprogesterone acetate (both arms)
Study: 8745317
Drug: Recombinant interferon‐alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant interferon‐alpha (rIFN) treatment
Study: 30712963
Drug: Intraperitoneal chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal chemotherapy after complete or optimal primary surgery
Study: 21868190
Drug: Suprascapular nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suprascapular nerve block (10 mL of 1% ropivacaine)